A Pharmacokinetic Model Determination of Time Activity Curves in Radiopharmaceutical Therapy
Introduction and Purpose Radiopharmaceutical therapy (RPT) dosimetry can be challenging to perform due to sparse data measurements and variations in how the time activity curve (TAC) is determined. In this work, a single system of equations was theoretically derived to estimate the TAC. Methods A ph...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-09-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.1177/15353508241280015 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849697993043738624 |
|---|---|
| author | Joseph Steiner Brandon Nguyen Farhad Jafari |
| author_facet | Joseph Steiner Brandon Nguyen Farhad Jafari |
| author_sort | Joseph Steiner |
| collection | DOAJ |
| description | Introduction and Purpose Radiopharmaceutical therapy (RPT) dosimetry can be challenging to perform due to sparse data measurements and variations in how the time activity curve (TAC) is determined. In this work, a single system of equations was theoretically derived to estimate the TAC. Methods A pharmacokinetic (PK) model was developed to estimate patient specific rate constants for a given set of body compartments. The PK model and an optimizer were numerically implemented to determine the rate constants and, using these physiologic data, to generate TACs and time integrated activities (TIAs) for 3 tissue systems from clinical data gathered in 5 patients. A fourth (aggregate) tissue compartment is added using conservation of activity considerations. Results Feasibility of the PK model was demonstrated by successfully generating TACs and TIAs for all patients in a manner comparable to existing methods in the literature. The data are compared to smaller sampling regimes. Differences between the 3- and 4-compartment models show that conservation of activity considerations should be part of TAC estimations. Conclusion The results here suggest a new paradigm in RPT in using the rate constants so identified as a diagnostic tool and as a vehicle to achieving individualized tumorcidal dose and/or the maximum tolerable dose to normal tissues. |
| format | Article |
| id | doaj-art-6f1505ad4c6c496cbb2f0aa04cbe6dd8 |
| institution | DOAJ |
| issn | 1536-0121 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-6f1505ad4c6c496cbb2f0aa04cbe6dd82025-08-20T03:19:03ZengSAGE PublishingMolecular Imaging1536-01212024-09-012310.1177/15353508241280015A Pharmacokinetic Model Determination of Time Activity Curves in Radiopharmaceutical TherapyJoseph Steiner0Brandon Nguyen1Farhad Jafari2 Department of Radiology, , Chicago, IL, USA Department of Radiology, , Minneapolis, MN, USA Department of Radiology, , Minneapolis, MN, USAIntroduction and Purpose Radiopharmaceutical therapy (RPT) dosimetry can be challenging to perform due to sparse data measurements and variations in how the time activity curve (TAC) is determined. In this work, a single system of equations was theoretically derived to estimate the TAC. Methods A pharmacokinetic (PK) model was developed to estimate patient specific rate constants for a given set of body compartments. The PK model and an optimizer were numerically implemented to determine the rate constants and, using these physiologic data, to generate TACs and time integrated activities (TIAs) for 3 tissue systems from clinical data gathered in 5 patients. A fourth (aggregate) tissue compartment is added using conservation of activity considerations. Results Feasibility of the PK model was demonstrated by successfully generating TACs and TIAs for all patients in a manner comparable to existing methods in the literature. The data are compared to smaller sampling regimes. Differences between the 3- and 4-compartment models show that conservation of activity considerations should be part of TAC estimations. Conclusion The results here suggest a new paradigm in RPT in using the rate constants so identified as a diagnostic tool and as a vehicle to achieving individualized tumorcidal dose and/or the maximum tolerable dose to normal tissues.https://doi.org/10.1177/15353508241280015 |
| spellingShingle | Joseph Steiner Brandon Nguyen Farhad Jafari A Pharmacokinetic Model Determination of Time Activity Curves in Radiopharmaceutical Therapy Molecular Imaging |
| title | A Pharmacokinetic Model Determination of Time Activity Curves in Radiopharmaceutical Therapy |
| title_full | A Pharmacokinetic Model Determination of Time Activity Curves in Radiopharmaceutical Therapy |
| title_fullStr | A Pharmacokinetic Model Determination of Time Activity Curves in Radiopharmaceutical Therapy |
| title_full_unstemmed | A Pharmacokinetic Model Determination of Time Activity Curves in Radiopharmaceutical Therapy |
| title_short | A Pharmacokinetic Model Determination of Time Activity Curves in Radiopharmaceutical Therapy |
| title_sort | pharmacokinetic model determination of time activity curves in radiopharmaceutical therapy |
| url | https://doi.org/10.1177/15353508241280015 |
| work_keys_str_mv | AT josephsteiner apharmacokineticmodeldeterminationoftimeactivitycurvesinradiopharmaceuticaltherapy AT brandonnguyen apharmacokineticmodeldeterminationoftimeactivitycurvesinradiopharmaceuticaltherapy AT farhadjafari apharmacokineticmodeldeterminationoftimeactivitycurvesinradiopharmaceuticaltherapy AT josephsteiner pharmacokineticmodeldeterminationoftimeactivitycurvesinradiopharmaceuticaltherapy AT brandonnguyen pharmacokineticmodeldeterminationoftimeactivitycurvesinradiopharmaceuticaltherapy AT farhadjafari pharmacokineticmodeldeterminationoftimeactivitycurvesinradiopharmaceuticaltherapy |